Ibsrela Side Effects

Generic name: tenapanor

Medically reviewed by Drugs.com. Last updated on Mar 13, 2025.

Note: This document provides detailed information about Ibsrela Side Effects associated with tenapanor. Some dosage forms listed on this page may not apply specifically to the brand name Ibsrela.

Applies to tenapanor: oral tablet.

Precautions

It is very important that your doctor check your progress at regular visits to make sure this medicine is working properly and to check for unwanted effects.

Call your doctor right away if you have severe diarrhea.

Serious side effects of Ibsrela

Along with its needed effects, tenapanor (the active ingredient contained in Ibsrela) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking tenapanor:

Other side effects of Ibsrela

Some side effects of tenapanor may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

For healthcare professionals

Applies to tenapanor: oral tablet.

General adverse events

The most commonly reported side effects included diarrhea, abdominal distention, flatulence, and dizziness.^[Ref]

Gastrointestinal

• Very common (10% or more): Diarrhea (up to 20%)
• Common (1% to 10%): Abdominal distention, flatulence, severe diarrhea
• Frequency not reported: Abnormal gastrointestinal sounds, rectal bleeding^[Ref]

Diarrhea occurred in 20% of patients with renal dysfunction (estimated glomerular function rate [eGFR] less than 90 mL/min/1.73 m2), compared to 16% of patients without renal dysfunction.^[Ref]

Metabolic

• Frequency not reported: Hyperkalemia resulting in hospitalization^[Ref]

In a clinical trial with patients with type 2 diabetes mellitus and chronic kidney disease (eGFR 25 to 70 mL/min/1.73 m2), hyperkalemia resulting in hospitalization was reported in 2 patients given this drug and 1 patient given placebo.^[Ref]

Nervous system

• Common (1% to 10%): Dizziness^[Ref]

See also:

Further information

Ibsrela side effects can vary depending on the individual. Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Note: Medication side effects may be underreported. If you are experiencing side effects that are not listed, submit a report to the FDA by following this guide.

Medical Disclaimer